The CureVac Vaccine

May 10, 2021

The German company, CureVac, is in the process of finalizing an RNA vaccine against COVID-19 with the culmination of its Phase 3 trial (1). The trial included 40,000 participants across Latin America and Europe. If the data shows the vaccine to be safe and effective, this may be the third RNA vaccine authorized for emergency use. Moreover, the CureVac vaccine is refrigerator-stable, making it more transportable than the Pfizer and Moderna vaccines. This gives CureVac a unique opportunity to supply vaccines to more remote locations, as well as locations that have yet to be supplied with ample doses, like lower and middle-income countries.
Data from the trial is expected by mid-May with promising results against variants such as the B.1.351 variant.